From ALS to Kidney Stones: How a Breakthrough Gene Therapy Trial Advances All Disease Research
July 28, 2026 — A Chinese research team led by Capital Medical University's Beijing Tiantan Hospital and Ractigen Therapeutics published results in Nature Medicine this week from the first-in-human trial of RAG-17, a small interfering RNA (siRNA) drug targeting SOD1 gene mutations in amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). The drug, delivered intrathecally (into the spinal fluid), demonstrated both safety and objective efficacy signals — a milestone for a disease that has resisted therapeutic intervention for decades. For kidney stone patients, the relevance is not immediately obvious — ALS is a neurodegenerative disease, not a kidney condition — but the underlying technology, siRNA-mediated gene silencing, has direct applications to oxalate metabolism that are already being explored in preclinical research.
How siRNA Technology Works — And Why It Matters for Oxalate
Small interfering RNA (siRNA) is a naturally occurring cellular mechanism for regulating gene expression. When a specific siRNA molecule enters a cell, it binds to messenger RNA (mRNA) — the intermediate molecule that carries genetic instructions from DNA to the protein-making machinery — and marks it for destruction. The gene is not edited or deleted; it is simply silenced, like turning off a light switch. The effect is temporary (weeks to months, depending on the specific siRNA design) and reversible, which is a safety advantage over permanent gene editing techniques like CRISPR.
For kidney stone disease, the therapeutic target is clear: the liver enzyme glycolate oxidase (GO), which catalyzes the conversion of glycolate to glyoxylate, the immediate precursor of oxalate. In primary hyperoxaluria type 1 (PH1) — a rare genetic disease causing catastrophic oxalate overproduction and kidney failure in children — the enzyme alanine-glyoxylate aminotransferase (AGT) is defective, allowing glyoxylate to accumulate and be converted to oxalate by lactate dehydrogenase (LDH). Two siRNA drugs targeting GO (lumasiran, approved 2020) and LDH (nedosiran, approved 2023) have already demonstrated that silencing oxalate-producing enzymes in the liver dramatically reduces urinary oxalate excretion — by 65-70% in PH1 patients on lumasiran.
The question that the RAG-17 ALS trial raises is: could siRNA technology be applied to dietary oxalate management in the far larger population of idiopathic calcium oxalate stone formers? If the hepatic enzymes responsible for endogenous oxalate production (which accounts for approximately 40-50% of urinary oxalate, with the remainder coming from dietary absorption) could be partially silenced, the reduction in urinary oxalate saturation could be clinically meaningful even in patients without a genetic oxalate disorder.
The Spectrum of Oxalate Management: From Diet to Drugs to Gene Silencing
| Intervention | Mechanism | Oxalate Reduction | Population |
|---|---|---|---|
| Low-oxalate diet | Reduce dietary oxalate intake | Variable | All stone formers |
| Dietary calcium with meals | Bind dietary oxalate in gut lumen | 20-40% | All stone formers |
| Probiotics (Oxalobacter) | Degrade oxalate in gut lumen | Variable (trials ongoing) | Selective responders |
| Potassium citrate | Bind urinary calcium, inhibit crystallization | Doesn't reduce oxalate directly | Hypocitraturic stone formers |
| Lumasiran (siRNA, GO) | Silence hepatic glycolate oxidase | 65-70% | PH1 only (FDA approved) |
| RAG-17 (siRNA, SOD1) | Silence mutant SOD1 in ALS | N/A | ALS (Phase I/II) |
What This Means for Kidney Stone Patients Today
The RAG-17 trial is a scientific achievement that does not change clinical practice for kidney stones in 2026. But it validates the siRNA platform — the same platform that produced lumasiran for PH1 — and accelerates investment in RNA-based therapeutics for metabolic diseases. For the 30 million Americans with kidney stones, the practical implication is that the research pipeline for oxalate-targeting therapies is active and progressing. Clinical trials for next-generation RNA therapies targeting oxalate metabolism in idiopathic stone formers (not just genetic hyperoxaluria patients) are likely within 5-8 years.
In the meantime, the most effective interventions remain the fundamentals: look up every food's oxalate content on OxalateWatch before building your meal plan; pair calcium-rich foods with any meal containing moderate oxalate; maintain 2.5-3 liters of water daily; monitor urine color for dilution adequacy; and work with your urologist on metabolic testing (24-hour urine collection) to identify your specific stone risk profile. The siRNA drugs will arrive. Until then, dietary management — informed by accurate, up-to-date oxalate data — is the most powerful tool you have.
Source: Nature Medicine (July 2026) RAG-17 Phase I results; Harvard T.H. Chan SPH (2024) oxalate data; New England Journal of Medicine (2020) lumasiran PH1 trial; Clinical Journal of the American Society of Nephrology (2023) nedosiran approval data.